Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $196.2 million.

  • Pharming Group N.V's Non-Current Assets rose 36.88% to $196.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.2 million, marking a year-over-year increase of 36.88%. This contributed to the annual value of $121.5 million for FY2024, which is 17.04% down from last year.
  • Per Pharming Group N.V's latest filing, its Non-Current Assets stood at $196.2 million for Q3 2025, which was down 2.14% from $200.5 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Non-Current Assets registered a high of $200.5 million during Q2 2025, and its lowest value of $130,275 during Q3 2022.
  • Moreover, its 3-year median value for Non-Current Assets was $146.5 million (2023), whereas its average is $158.2 million.
  • In the last 5 years, Pharming Group N.V's Non-Current Assets crashed by 99.92% in 2022 and then soared by 110,995.76% in 2023.
  • Pharming Group N.V's Non-Current Assets (Quarterly) stood at $147.9 million in 2021, then rose by 0.29% to $148.3 million in 2022, then declined by 1.20% to $146.5 million in 2023, then fell by 17.04% to $121.5 million in 2024, then spiked by 36.88% to $196.2 million in 2025.
  • Its last three reported values are $196.2 million in Q3 2025, $200.5 million for Q2 2025, and $189.1 million during Q1 2025.